Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Lee Website

Daniel W. Lee, M.D.

Selected Publications

1)  Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL.
How I treat: current concepts in the diagnosis and management of cytokine release syndrome.
Blood. [Epub ahead of print], 2014.
2)  Tumaini B, Lee DW, Lin T, Castiello L, Stroncek DF, Mackall C, Wayne A, Sabatino M.
Simplified process for the production of anti-CD19-CAR-engineered T cells.
Cytotherapy. 15: 1406-15, 2013.
3)  Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA.
The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.
Clin. Cancer Res. 18: 2780-90, 2012.
4)  Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, Fitzgerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ.
Anti-CD22-chimeric antigen receptors targeting B cell precursor acute lymphoblastic leukemia.
Blood. 121: 1165-74, 2012.
5)  Lee DW, Futami M, Carroll M, Feng Y, Wang Z, Fernandez M, Whichard Z, Chen Y, Kornblau S, Shpall EJ, Bueso-Ramos CE, Corey SJ.
Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155.
Oncogene. 31: 4085-94, 2012.
6)  Mehta HM, Futami M, Glaubach T, Lee DW, Andolina JR, Yang Q, Whichard Z, Quinn M, Lu HF, Kao WM, Przychodzen B, Sarkar CA, Minella A, Maciejewski JP, Corey SJ.
Alternatively spliced, truncated GCSF receptor promotes leukemogenic properties and sensitivity to JAK inhibition.
Leukemia. 28: 1041-1051, 2014.
7)  Orentas RJ, Lee DW, Mackall C.
Immunotherapy targets in pediatric cancer.
Front Oncol. 2: 3, 2012.
Click Here to View Collapsed Bibliography.

This page was last updated on 6/20/2014.